GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products for the early detection of cancer. The Company's investors include Amazon, Bezos Expeditions, Bill Gates Foundation, alongside strategic investors including Bristol-Myers Squibb, Arch Venture Partners, Celgene, Illumina, Johnson & Johnson Innovation, and Merck.